-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, March 10 Recently, Kelun Pharmaceutical entered the administrative examination and approval stage with the imitation of the 4 types of sunitinib malate capsules.
It is expected to be approved in the near future and become the third domestic manufacturer.
According to data from Meinnet.
com, Pfizer's sunitinib malate capsules will have global sales of US$819 million in 2020.
In 2019, the sales of sunitinib in Chinese public medical institutions will be close to 400 million yuan, a year-on-year increase of 51.
83%.
It is expected to be approved in the near future and become the third domestic manufacturer.
According to data from Meinnet.
com, Pfizer's sunitinib malate capsules will have global sales of US$819 million in 2020.
In 2019, the sales of sunitinib in Chinese public medical institutions will be close to 400 million yuan, a year-on-year increase of 51.
83%.
Sunitinib is a multi-target receptor tyrosine kinase inhibitor developed by Pfizer.
It is mainly used clinically to treat adult patients with gastrointestinal stromal tumors, renal cell carcinoma and pancreatic neuroendocrine tumors.
According to data from Meinnet.
com, Pfizer's global sales of sunitinib malate capsules were up to US$1.
236 billion in 2012, and sales in 2020 were US$819 million.
It is mainly used clinically to treat adult patients with gastrointestinal stromal tumors, renal cell carcinoma and pancreatic neuroendocrine tumors.
According to data from Meinnet.
com, Pfizer's global sales of sunitinib malate capsules were up to US$1.
236 billion in 2012, and sales in 2020 were US$819 million.
Terminal sunitinib sales in public medical institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
In recent years, the domestic market for sunitinib has continued to expand.
According to data from Meinenet, in 2019, the sales of terminal sunitinib in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) approached 400 million yuan, an increase of 51.
83% year-on-year; 2020H1 Sales were 233 million yuan, a year-on-year increase of 47.
67%.
According to data from Meinenet, in 2019, the sales of terminal sunitinib in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) approached 400 million yuan, an increase of 51.
83% year-on-year; 2020H1 Sales were 233 million yuan, a year-on-year increase of 47.
67%.
Application status of 4 types of imitation of sunitinib malate capsules
Source: One-click search on Mi Nei.
com
com
At present, a total of 5 pharmaceutical companies in the domestic market have submitted applications for the listing of sunitinib malate capsules.
CSPC won the first imitation in December 2019, and Hausen Pharmaceuticals is the second domestic manufacturer of this variety.
Zhengda Tianqing Pharmaceutical Group and Qilu Pharmaceutical are under review and approval of the product listing application.
The registration status of sunitinib malate capsules of Kelun Pharmaceutical has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and become the third domestic company.
CSPC won the first imitation in December 2019, and Hausen Pharmaceuticals is the second domestic manufacturer of this variety.
Zhengda Tianqing Pharmaceutical Group and Qilu Pharmaceutical are under review and approval of the product listing application.
The registration status of sunitinib malate capsules of Kelun Pharmaceutical has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and become the third domestic company.
Source: Mi Neiwang database, NMPA
Medical Network News, March 10 Recently, Kelun Pharmaceutical entered the administrative examination and approval stage with the imitation of the 4 types of sunitinib malate capsules.
It is expected to be approved in the near future and become the third domestic manufacturer.
According to data from Meinnet.
com, Pfizer's sunitinib malate capsules will have global sales of US$819 million in 2020.
In 2019, the sales of sunitinib in Chinese public medical institutions will be close to 400 million yuan, a year-on-year increase of 51.
83%.
It is expected to be approved in the near future and become the third domestic manufacturer.
According to data from Meinnet.
com, Pfizer's sunitinib malate capsules will have global sales of US$819 million in 2020.
In 2019, the sales of sunitinib in Chinese public medical institutions will be close to 400 million yuan, a year-on-year increase of 51.
83%.
Sunitinib is a multi-target receptor tyrosine kinase inhibitor developed by Pfizer.
It is mainly used clinically to treat adult patients with gastrointestinal stromal tumors, renal cell carcinoma and pancreatic neuroendocrine tumors.
According to data from Meinnet.
com, Pfizer's global sales of sunitinib malate capsules were up to US$1.
236 billion in 2012, and sales in 2020 were US$819 million.
It is mainly used clinically to treat adult patients with gastrointestinal stromal tumors, renal cell carcinoma and pancreatic neuroendocrine tumors.
According to data from Meinnet.
com, Pfizer's global sales of sunitinib malate capsules were up to US$1.
236 billion in 2012, and sales in 2020 were US$819 million.
Terminal sunitinib sales in public medical institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
In recent years, the domestic market for sunitinib has continued to expand.
According to data from Meinenet, in 2019, the sales of terminal sunitinib in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) approached 400 million yuan, an increase of 51.
83% year-on-year; 2020H1 Sales were 233 million yuan, a year-on-year increase of 47.
67%.
According to data from Meinenet, in 2019, the sales of terminal sunitinib in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) approached 400 million yuan, an increase of 51.
83% year-on-year; 2020H1 Sales were 233 million yuan, a year-on-year increase of 47.
67%.
Application status of 4 types of imitation of sunitinib malate capsules
Source: One-click search on Mi Nei.
com
com
At present, a total of 5 pharmaceutical companies in the domestic market have submitted applications for the listing of sunitinib malate capsules.
CSPC won the first imitation in December 2019, and Hausen Pharmaceuticals is the second domestic manufacturer of this variety.
Zhengda Tianqing Pharmaceutical Group and Qilu Pharmaceutical are under review and approval of the product listing application.
The registration status of sunitinib malate capsules of Kelun Pharmaceutical has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and become the third domestic company.
CSPC won the first imitation in December 2019, and Hausen Pharmaceuticals is the second domestic manufacturer of this variety.
Zhengda Tianqing Pharmaceutical Group and Qilu Pharmaceutical are under review and approval of the product listing application.
The registration status of sunitinib malate capsules of Kelun Pharmaceutical has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and become the third domestic company.
Source: Mi Neiwang database, NMPA
Medical Network News, March 10 Recently, Kelun Pharmaceutical entered the administrative examination and approval stage with the imitation of the 4 types of sunitinib malate capsules.
It is expected to be approved in the near future and become the third domestic manufacturer.
According to data from Meinnet.
com, Pfizer's sunitinib malate capsules will have global sales of US$819 million in 2020.
In 2019, the sales of sunitinib in Chinese public medical institutions will be close to 400 million yuan, a year-on-year increase of 51.
83%.
It is expected to be approved in the near future and become the third domestic manufacturer.
According to data from Meinnet.
com, Pfizer's sunitinib malate capsules will have global sales of US$819 million in 2020.
In 2019, the sales of sunitinib in Chinese public medical institutions will be close to 400 million yuan, a year-on-year increase of 51.
83%.
Sunitinib is a multi-target receptor tyrosine kinase inhibitor developed by Pfizer.
It is mainly used clinically to treat adult patients with gastrointestinal stromal tumors, renal cell carcinoma and pancreatic neuroendocrine tumors.
According to data from Meinnet.
com, Pfizer's global sales of sunitinib malate capsules were up to US$1.
236 billion in 2012, and sales in 2020 were US$819 million.
It is mainly used clinically to treat adult patients with gastrointestinal stromal tumors, renal cell carcinoma and pancreatic neuroendocrine tumors.
According to data from Meinnet.
com, Pfizer's global sales of sunitinib malate capsules were up to US$1.
236 billion in 2012, and sales in 2020 were US$819 million.
Terminal sunitinib sales in public medical institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
In recent years, the domestic market for sunitinib has continued to expand.
According to data from Meinenet, in 2019, the sales of terminal sunitinib in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) approached 400 million yuan, an increase of 51.
83% year-on-year; 2020H1 Sales were 233 million yuan, a year-on-year increase of 47.
67%.
Hospital hospital hospitalAccording to data from Meinenet, in 2019, the sales of terminal sunitinib in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) approached 400 million yuan, an increase of 51.
83% year-on-year; 2020H1 Sales were 233 million yuan, a year-on-year increase of 47.
67%.
Application status of 4 types of imitation of sunitinib malate capsules
Source: One-click search on Mi Nei.
com
com
At present, a total of 5 pharmaceutical companies in the domestic market have submitted applications for the listing of sunitinib malate capsules.
CSPC won the first imitation in December 2019, and Hausen Pharmaceuticals is the second domestic manufacturer of this variety.
Zhengda Tianqing Pharmaceutical Group and Qilu Pharmaceutical are under review and approval of the product listing application.
The registration status of sunitinib malate capsules of Kelun Pharmaceutical has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and become the third domestic company.
CSPC won the first imitation in December 2019, and Hausen Pharmaceuticals is the second domestic manufacturer of this variety.
Zhengda Tianqing Pharmaceutical Group and Qilu Pharmaceutical are under review and approval of the product listing application.
The registration status of sunitinib malate capsules of Kelun Pharmaceutical has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and become the third domestic company.
Source: Mi Neiwang database, NMPA
